Fortress Biotech Inc (FBIO) is Initiated by ROTH Capital to Buy, Price Target at $9

Fortress Biotech Inc (FBIO) was Initiated by ROTH Capital to “Buy” and the brokerage firm has set the Price Target at $9. ROTH Capital advised their investors in a research report released on Oct 3, 2016.

Fortress Biotech Inc opened for trading at $2.87 and hit $2.99 on the upside on Friday, eventually ending the session at $2.97, with a gain of 4.21% or 0.12 points. The heightened volatility saw the trading volume jump to 58,594 shares. Company has a market cap of $145 M.

In a different news, on Sep 19, 2016, George Avgerinos (SVP, Biologics Operations) sold 48,912 shares at $2.55 per share price. According to the SEC, on Jun 17, 2016, Lindsay A Md Rosenwald (CEO) purchased 613 shares at $2.40 per share price.

Fortress Biotech Inc. formerly Coronado Biosciences Inc. is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer namely CNDO-201 or Trichuris suis ova (TSO) and CNDO-109. As of December 31 2014 TSO the microscopic eggs of the porcine whipworm was in Phase II study stage for the treatment of immune-mediated diseases such as Crohn’s disease (CD) ulcerative colitis (UC) or autism spectrum disorder (ASD). The Company’s CNDO-109 is a biologic that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells and as of December 31 2014 was in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML). The Company’s subsidiary Journey Medical Corporation (JMC) focuses on acquiring developing licensing and commercializing branded dermatology products.

Fortress Biotech Inc

Leave a Reply

Fortress Biotech Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Fortress Biotech Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.